We successfully raised money to fund and execute Arcadia – a Ph II clinical trial in 2020.
ARCADIA – a Phase II clinical trial – investigated the use of AZD1656 in diabetic patients hospitalised with COVID19. 153 patients were recruited during 2020-21 across 30 sites in UK, Romania and Czech Republic. The trial was part funded by UKRI.
Results from the ARCADIA trial include:
- Reduced mortality and faster hospital discharge time for key vulnerable groups.
- A noticeable Immunomodulatory effect with a trend towards restored immune homeostasis in AZD1656 treated group.
